Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways
Open Access
- 2 September 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 26 (3), 644-656
- https://doi.org/10.1002/jbmr.242
Abstract
Activation of NF‐κB and MAPK/activator protein 1 (AP‐1) signaling pathways by receptor activator NF‐κB ligand (RANKL) is essential for osteoclast activity. Targeting NF‐κB and MAPK/AP‐1 signaling to modulate osteoclast activity has been a promising strategy for osteoclast‐related diseases. In this study we examined the effects of maslinic acid (MA), a pentacyclic triterpene acid that is widely present in dietary plants, on RANKL‐induced osteoclastogenesis, osteoclast function, and signaling pathways by in vitro and in vivo assay systems. In mouse bone marrow monocytes (BMMs) and RAW264.7 cells, MA inhibited RANKL‐induced osteoclastogenesis in a dose‐dependent manner within nongrowth inhibitory concentration, and MA decreased osteoclastogenesis‐related marker gene expression, including TRACP, MMP9, c‐Src, CTR, and cathepsin K. Specifically, MA suppressed osteoclastogenesis and actin ring formation at early stage. In ovariectomized mice, administration of MA prevented ovariectomy‐induced bone loss by inhibiting osteoclast activity. At molecular levels, MA abrogated the phosphorylation of MAPKs and AP‐1 activity, inhibited the IκBα phosphorylation and degradation, blocked NF‐κB/p65 phosphorylation, nuclear translocation, and DNA‐binding activity by downregulating RANK expression and blocking RANK interaction with TRAF6. Together our data demonstrate that MA suppresses RANKL‐induced osteoclastogenesis through NF‐κB and MAPK/AP‐1 signaling pathways and that MA is a promising agent in the treatment of osteoclast‐related diseases such as osteoporosis. © 2011 American Society for Bone and Mineral Research.Keywords
This publication has 44 references indexed in Scilit:
- Maslinic acid potentiates the anti-tumor activity of tumor necrosis factor α by inhibiting NF-κB signaling pathwayMolecular Cancer, 2010
- Epigallocatechin-3-gallate Inhibits Osteoclastogenesis by Down-Regulating c-Fos Expression and Suppressing the Nuclear Factor-κB SignalMolecular Pharmacology, 2009
- Regulation of bone formation and remodeling by G-protein-coupled receptor 48Development, 2009
- Cathepsin K Activity-dependent Regulation of Osteoclast Actin Ring Formation and Bone ResorptionJournal of Biological Chemistry, 2009
- Intermittent recombinant TSH injections prevent ovariectomy-induced bone lossProceedings of the National Academy of Sciences of the United States of America, 2008
- Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systemsNature Reviews Immunology, 2007
- A TNF receptor loop peptide mimic blocks RANK ligand–induced signaling, bone resorption, and bone lossJCI Insight, 2006
- Estrogen Regulation of Immune Cell Bone InteractionsAnnals of the New York Academy of Sciences, 2006
- FHL2 inhibits the activated osteoclast in a TRAF6-dependent mannerJCI Insight, 2005
- Osteoclast differentiation and activationNature, 2003